Cyclerion Therapeutics (CYCN) Competitors $3.19 +0.24 (+8.14%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYCN vs. ATNM, VYNE, OCX, ELEV, CALC, LUMO, LTRN, MRKR, BRNS, and TPSTShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Actinium Pharmaceuticals (ATNM), VYNE Therapeutics (VYNE), OncoCyte (OCX), Elevation Oncology (ELEV), CalciMedica (CALC), Lumos Pharma (LUMO), Lantern Pharma (LTRN), Marker Therapeutics (MRKR), Barinthus Biotherapeutics (BRNS), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Actinium Pharmaceuticals VYNE Therapeutics OncoCyte Elevation Oncology CalciMedica Lumos Pharma Lantern Pharma Marker Therapeutics Barinthus Biotherapeutics Tempest Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Does the MarketBeat Community believe in ATNM or CYCN? Cyclerion Therapeutics received 29 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 58.62% of users gave Cyclerion Therapeutics an outperform vote while only 38.46% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% Cyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Do analysts prefer ATNM or CYCN? Actinium Pharmaceuticals presently has a consensus price target of $7.40, indicating a potential upside of 473.64%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, ATNM or CYCN? Actinium Pharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ATNM or CYCN? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ATNM or CYCN more profitable? Cyclerion Therapeutics' return on equity of -55.32% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Cyclerion Therapeutics N/A -55.32%-48.35% Which has stronger valuation and earnings, ATNM or CYCN? Cyclerion Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K496.83-$48.82M-$1.39-0.93Cyclerion Therapeutics$194K44.56-$5.26MN/AN/A Does the media favor ATNM or CYCN? In the previous week, Cyclerion Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Cyclerion Therapeutics and 0 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score. Company Overall Sentiment Actinium Pharmaceuticals Neutral Cyclerion Therapeutics Neutral SummaryCyclerion Therapeutics beats Actinium Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Investors AlleyCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…Click here to discover the new #1 way to invest in Tesla Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.00M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales44.56196.061,117.09117.05Price / CashN/A57.1643.1037.85Price / Book0.695.094.784.78Net Income-$5.26M$151.83M$120.31M$225.60M7 Day Performance-7.00%-2.14%-1.92%-1.23%1 Month Performance123.08%-4.56%13.65%0.46%1 Year Performance-25.12%8.87%28.34%15.24% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics0.6403 of 5 stars$3.19+8.1%N/A-22.2%$8.00M$194,000.000.0030Gap DownATNMActinium Pharmaceuticals1.2452 of 5 stars$1.23-0.4%$7.40+504.1%N/A$38.22M$81,000.00-0.8849VYNEVYNE Therapeutics2.6593 of 5 stars$2.57+0.4%$6.88+167.5%-1.6%$37.91M$493,000.00-2.9830News CoverageOCXOncoCyte3.2612 of 5 stars$2.25-3.0%$4.42+96.3%-23.2%$37.87M$1.50M0.00120Analyst ForecastELEVElevation Oncology1.9868 of 5 stars$0.64+0.6%$7.20+1,025.0%+30.0%$37.84MN/A-0.7840Analyst ForecastCALCCalciMedica2.9484 of 5 stars$2.80+2.6%$19.33+590.5%-7.1%$37.75MN/A-2.5330Positive NewsLUMOLumos Pharma3.0986 of 5 stars$4.34flat$8.63+98.7%+45.6%$37.54M$2.21M-1.0130High Trading VolumeLTRNLantern PharmaN/A$3.47+0.6%N/A-24.0%$37.42MN/A-1.9420Gap DownMRKRMarker Therapeutics4.0361 of 5 stars$4.19+2.9%$19.00+353.5%-4.8%$37.38M$3.31M0.0060News CoveragePositive NewsBRNSBarinthus Biotherapeutics1.5315 of 5 stars$0.93+1.6%$5.83+529.3%-66.8%$37.29M$800,000.00-0.61107Gap UpTPSTTempest Therapeutics1.8299 of 5 stars$0.85+5.8%$20.00+2,263.5%-80.8%$36.93MN/A0.0020 Related Companies and Tools Related Companies ATNM Competitors VYNE Competitors OCX Competitors ELEV Competitors CALC Competitors LUMO Competitors LTRN Competitors MRKR Competitors BRNS Competitors TPST Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
